Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

June 2010

Palatin Technologies, Inc. Announces Last Patient Dosed and Database Lock in Subcutaneous Bremelanotide Trial in Men

Press Releases / By

CRANBURY, N.J., June 24 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter. The …

Palatin Technologies, Inc. Announces Last Patient Dosed and Database Lock in Subcutaneous Bremelanotide Trial in Men Read More »

Palatin Technologies, Inc. Announces Positive Preclinical Data with PL-3994 for Asthma Indications

Press Releases / By

CRANBURY, N.J., June 21 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results of preclinical studies in respiratory tissue with PL-3994.  In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans. PL-3994 is a proprietary peptide mimetic …

Palatin Technologies, Inc. Announces Positive Preclinical Data with PL-3994 for Asthma Indications Read More »

Scroll to Top